Trial Profile
Subconjunctival Aflibercept Injection for Corneal Neovascularization
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ciclosporin; Steroids
- Indications Corneal neovascularisation
- Focus Adverse reactions
- 06 Oct 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 04 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 04 Mar 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.